​

Repligen (RGEN) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

RGEN Stock Forecast

Repligen (RGEN) stock forecast, based on 23 Wall Street analysts, predicts a 12-month average price target of $171.00, with a high of $205.00 and a low of $150.00. This represents a 12.82% increase from the last price of $151.57.

$125 $141 $157 $173 $189 $205 High: $205 Avg: $171 Low: $150 Last Closed Price: $151.57

RGEN Stock Rating

Repligen stock's rating consensus is Buy, based on 23 Wall Street analysts. The breakdown includes 1 Strong Buy (4.35%), 19 Buy (82.61%), 3 Hold (13.04%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 23 0 3 19 1 Strong Sell Sell Hold Buy Strong Buy

RGEN Price Target Upside V Benchmarks

TypeNameUpside
StockRepligen12.82%
SectorHealthcare Stocks 15.45%
IndustryMedical Instruments & Supplies Stocks22.33%

Price Target Trends

1M3M12M
# Anlaysts567
Avg Price Target$162.00$169.17$176.43
Last Closing Price$151.57$151.57$151.57
Upside/Downside6.88%11.61%16.40%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 254134--21
Sep, 255115--21
Aug, 255115--21
Jul, 255105--20
Jun, 254105--19
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 29, 2025Canaccord Genuity$165.00$151.578.86%8.86%
Oct 29, 2025Barclays$175.00$151.5715.46%15.46%
Oct 28, 2025Matthew StantonJefferies$160.00$154.243.73%5.56%
Oct 02, 2025Luke SergottBarclays$160.00$145.819.73%5.56%
Oct 01, 2025HSBC$150.00$133.6712.22%-1.04%
Sep 02, 2025RBC Capital$205.00$120.6969.86%35.25%
Nov 12, 2024Paul KnightKeyBanc$220.00$148.5948.06%45.15%
Jul 31, 2024Rachel VatnsdalJ.P. Morgan$200.00$167.3519.51%31.95%
Jul 31, 2024Elizabeth GarciaUBS$185.00$167.3510.55%22.06%
Jun 26, 2024Justin BowersDeutsche Bank$155.00$127.0022.05%2.26%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 29, 2025BarclaysOverweightOverweighthold
Oct 28, 2025JefferiesHoldHoldhold
Oct 02, 2025BarclaysOverweightOverweighthold
Oct 01, 2025HSBCBuyinitialise
Sep 22, 2025Evercore ISIOutperformupgrade
Sep 02, 2025RBC CapitalOutperformOutperformhold
Nov 12, 2024KeyBancOverweightOverweighthold
Sep 26, 2024UBSUnderperformUnderperformhold
Aug 27, 2024Wells FargoOverweightinitialise
Jul 31, 2024UBSBuyBuyhold

Financial Forecast

EPS Forecast

$-1 $0 $1 $2 $3 $4 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$1.14$2.33$3.35$0.64$-0.46----
Avg Forecast$1.44$2.90$3.18$1.73$1.54$1.74$2.22$2.70$3.47
High Forecast$1.47$2.96$3.24$1.77$1.58$1.83$2.45$3.06$3.54
Low Forecast$1.40$2.82$3.12$1.70$1.51$1.58$1.78$2.26$3.38
Surprise %-20.83%-19.66%5.35%-63.01%-129.87%----

Revenue Forecast

$300M $460M $620M $780M $940M $1B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$366.26M$670.53M$801.54M$632.36M$634.44M----
Avg Forecast$351.59M$664.36M$799.57M$638.45M$634.11M$695.52M$795.79M$906.21M$1.06B
High Forecast$357.01M$674.59M$810.89M$640.73M$636.51M$700.21M$798.66M$924.49M$1.08B
Low Forecast$344.55M$651.05M$787.36M$634.53M$632.52M$683.80M$792.92M$887.93M$1.04B
Surprise %4.17%0.93%0.25%-0.95%0.05%----

Net Income Forecast

$-50M $0 $50M $100M $150M $200M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$59.93M$128.29M$185.96M$35.60M$-25.51M----
Avg Forecast$36.77M$80.76M$123.55M$41.58M$87.14M$96.13M$119.29M$149.89M$195.63M
High Forecast$44.12M$96.91M$148.26M$49.89M$89.12M$102.99M$138.23M$172.50M$199.72M
Low Forecast$29.41M$64.61M$98.84M$33.26M$85.17M$89.26M$100.34M$127.28M$190.28M
Surprise %62.99%58.85%50.52%-14.39%-129.28%----

RGEN Forecast FAQ

Is Repligen stock a buy?

Repligen stock has a consensus rating of Buy, based on 23 Wall Street analysts. The rating breakdown includes 1 Strong Buy, 19 Buy, 3 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Repligen is a favorable investment for most analysts.

What is Repligen's price target?

Repligen's price target, set by 23 Wall Street analysts, averages $171 over the next 12 months. The price target range spans from $150 at the low end to $205 at the high end, suggesting a potential 12.82% change from the previous closing price of $151.57.

How does Repligen stock forecast compare to its benchmarks?

Repligen's stock forecast shows a 12.82% upside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the medical instruments & supplies stocks industry (22.33%).

What is the breakdown of analyst ratings for Repligen over the past three months?

  • October 2025: 19.05% Strong Buy, 61.90% Buy, 19.05% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 23.81% Strong Buy, 52.38% Buy, 23.81% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 23.81% Strong Buy, 52.38% Buy, 23.81% Hold, 0% Sell, 0% Strong Sell.

What is Repligen’s EPS forecast?

Repligen's average annual EPS forecast for its fiscal year ending in December 2025 is $1.74, marking a -478.26% decrease from the reported $-0.46 in 2024. Estimates for the following years are $2.22 in 2026, $2.7 in 2027, and $3.47 in 2028.

What is Repligen’s revenue forecast?

Repligen's average annual revenue forecast for its fiscal year ending in December 2025 is $695.52M, reflecting a 9.63% increase from the reported $634.44M in 2024. The forecast for 2026 is $795.79M, followed by $906.21M for 2027, and $1.06B for 2028.

What is Repligen’s net income forecast?

Repligen's net income forecast for the fiscal year ending in December 2025 stands at $96.13M, representing a -476.76% decrease from the reported $-25.514M in 2024. Projections indicate $119.29M in 2026, $149.89M in 2027, and $195.63M in 2028.